ESMO Sarcoma and Rare Cancers 2023 | What is tumour-agnostic treatment and how is it utilised in rare tumors?

Claudia María Valverde Morales, MD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the background behind tumor-agnostic treatment while highlighting the challenges this therapy presents in the context of rarer malignancies. Dr Valverde Morales defines this intervention approach as a form of precision medicine which is genetically focused and concerned with the treatment of patients with cancer according to the molecular characteristics of their tumor. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.